Indivior has been embroiled in a lengthy battle to extract itself from a raft of court cases associated with its treatment for opioid or painkiller addiction.
That drug, Suboxone, is now off-patent but is declining slower than expected, which has seen the share price perk up recently.
Analysts are expecting turnover to rise 17.1% year-on-year to US$757.8mln this time and pre-tax profit to clock in at US$147.0mln, compared to a loss the year before of US$173mln.
At the time of its third-quarter results, the company raised its 2021 revenue guidance on the back of strong demand for its new SUBLOCADE drug, an alternative to regular opioids and shareholders will be hoping that the momentum has been continued.
UK inflation
Inflation at the end of last year rising to its highest levels since 1992, moving up to 5.4% from 5.1%, was a prime reason why the Bank of England took the decision to raise interest rates by 0.25% to 0.5% at the start of this month.
With four rate-setters wanting to go further and hike to 0.75%, a similarly strong reading of the consumer prices index could provide a stronger signal of another rate rise next month.
This week’s January numbers are expected to see UK CPI come in at 5.5%, with core prices rising to 4.3%.
The Bank of England has already forecast that inflation will peak at around 7.25% around April as energy bills jump that month.
Wednesday 16 February
Trading announcements: Ocean Outdoor Ltd (LSE:OOUT) (Ocean Outdoor Ltd (LSE:OOUT))
Finals: Primary Health Properties PLC (LSE:PHP) (Primary Health Properties PLC (LSE:PHP)), Segro PLC, Indivior PLC (LSE:INDV) (Indivior PLC (LSE:INDV))
Economic Announcements: Consumer Price Index, Producer Price Index, Retail Price Index, January Retail Sales (US), FOMC Minutes (US)